Thyroid fine needle aspirate: A post-Bethesda update

Advances in Anatomic Pathology

Volumn 19, Issue 3, 2012, Pages 160-169

  Bose, Shikha ^a   Walts, Ann E ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

bethesda; BRAF; fine needle aspirate; genetic abnormalities; KRAS; thyroid

Indexed keywords

MICRORNA; MOLECULAR MARKER; PROTEIN PATCHED; PROTEIN RET; RAS PROTEIN; TRANSCRIPTION FACTOR PAX8;

ASPIRATION BIOPSY; CYTOPATHOLOGY; HUMAN; MORPHOLOGY; MUTATION; PRIORITY JOURNAL; REVIEW; THYROID FINE NEEDLE ASPIRATE; THYROID FOLLICLE CELL; THYROID FOLLICULAR CARCINOMA; THYROID GLAND; THYROID PAPILLARY CARCINOMA;

BIOPSY, FINE-NEEDLE; DNA-BINDING PROTEINS; FEMALE; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; NUCLEAR PROTEINS; OBSERVER VARIATION; PAIRED BOX TRANSCRIPTION FACTORS; PPAR GAMMA; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS B-RAF; THYROID GLAND; THYROID NEOPLASMS; THYROID NODULE; TRANSLOCATION, GENETIC;

EID: 84860011284     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e3182534610     Document Type: Review

References (109)

1. SEER Stat Fact Sheets: Thyroid. 2012; Available at: http:// seer.cancer.gov/statfacts/html/thyro.html. Accessed November 10, 2011.
2. Kilfoy BA, Zheng T, Holford TR, et al. International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control. 2009;20:525-531.
3. Gilliland FD, Hunt WC, Morris DM, et al. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer. 1997;79:564-573. (Pubitemid 27051783)
4. Smith BD, Smith GL, Hurria A, et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27:2758-2765.
5. Gharib H, Papini E, Valcavi R, et al. American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract. 2006;12:63-102.
6. Baloch ZW, Cibas ES, Clark DP, et al. The National Cancer Institute Thyroid fine needle aspiration state of the science conference: a summation. Cytojournal. 2008;5:6.
7. Cibas ES, Ali SZ. The Bethesda system for reporting thyroid cytopathology. Am J Clin Pathol. 2009;132:658-665.
8. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-1214.
9. Ozluk Y, Pehlivan E, Gulluoglu MG, et al. The use of the Bethesda terminology in thyroid fine-needle aspiration results in a lower rate of surgery for nonmalignant nodules: a report from a reference center in Turkey. Int J Surg Pathol. 2011; 19:761-771.
10. Crowe A, Linder A, Hameed O, et al. The impact of implementation of the Bethesda System for Reporting Thyroid Cytopathology on the quality of reporting, 'risk' of malignancy, surgical rate, and rate of frozen sections requested for thyroid lesions. Cancer Cytopathol. 2011;119: 315-321.
11. Theoharis CG, Schofield KM, Hammers L, et al. The Bethesda thyroid fine-needle aspiration classification system: year 1 at an academic institution. Thyroid. 2009;19:1215-1223.
12. Renshaw AA. Sensitivity of fine-needle aspiration for papillary carcinoma of the thyroid correlates with tumor size. Diagn Cytopathol. 2011;39:471-474.
13. Dustin SM, Jo VY, Hanley KZ, et al. High sensitivity and positive predictive value of fine-needle aspiration for uncommon thyroid malignancies. Diagn Cytopathol. 2011 [Epub ahead of print].
14. Renshaw A. An estimate of risk of malignancy for a benign diagnosis in thyroid fine-needle aspirates. Cancer Cytopathol. 2010;118:190-195.
15. Alexander EK, Heering JP, Benson CB, et al. Assessment of nondiagnostic ultrasound-guided fine needle aspirations of thyroid nodules. J Clin Endocrinol Metab. 2002;87:4924-4927. (Pubitemid 35316326)
16. Chernyavsky VS, Shanker BA, Davidov T, et al. Is one benign fine needle aspiration enough? Ann Surg Oncol. 2011 Published online.
17. Redman R, Zalaznick H, Mazzaferri EL, et al. The impact of assessing specimen adequacy and number of needle passes for fine-needle aspiration biopsy of thyroid nodules. Thyroid. 2006;16:55-60. (Pubitemid 43346504)
18. Baloch ZW, Tam D, Langer J, et al. Ultrasound-guided fineneedle aspiration biopsy of the thyroid: role of on-site assessment and multiple cytologic preparations. Diagn Cytopathol. 2000; 23:425-429.
19. de los Santos ET, Keyhani-Rofagha S, Cunningham JJ, et al. Cystic thyroid nodules. The dilemma of malignant lesions. Arch Intern Med. 1990;150:1422-1427. (Pubitemid 20215681)
20. Yeh MW, Demircan O, Ituarte P, et al. False-negative fineneedle aspiration cytology results delay treatment and adversely affect outcome in patients with thyroid carcinoma. Thyroid. 2004;14:207-215. (Pubitemid 38452193)
21. Nayar R, Ivanovic M. The indeterminate thyroid fine-needle aspiration experience from an academic center using terminology similar to that proposed in the 2007 National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference. Cancer. 2009;117:195-202.
22. Faquin WC, Baloch ZW. Fine-needle aspiration of follicular patterned lesions of the thyroid: diagnosis, management, and follow-up according to National Cancer Institute (NCI) recommendations. Diagn Cytopathol. 2010;38:731-739.
23. Jo VY, Stelow EB, Dustin SM, et al. Malignancy risk for fineneedle aspiration of thyroid lesions according to the Bethesda system for reporting thyroid cytopathology. Am J Clin Pathol. 2010;134:450-456.
24. Layfield LJ, Morton MJ, Cramer HM, et al. Implications of the proposed thyroid fine-needle aspiration category of 'follicular lesion of undetermined significance': a five-year multi-institutional analysis. Diagn Cytopathol. 2009;37: 710-714.
25. Renshaw AA. Should 'atypical follicular cells' in thyroid fineneedle aspirates be subclassified? Cancer Cytopathol. 2010; 118:186-189.
26. Krane JF, Vanderlaan PA, Faquin WC, et al. The atypia of undetermined significance/follicular lesion of undetermined significance: malignant ratio: a proposed performance measure for reporting in the Bethesda system for thyroid cytopathology. Cancer Cytopathol. 2011 [Epub ahead of print].
27. Ali SZ. The Bethesda System for Reporting Thyroid Cytopathology Definitions, Criteria and Explanatory Notes. New York: Springer; 2010.
28. Broome JT, Solorzano CC. The impact of atypia/follicular lesion of undetermined significance on the rate of malignancy in thyroid fine-needle aspiration: evaluation of the Bethesda system for reporting thyroid cytopathology. Surgery. 2011;150:1234-1241.
29. Mete O, Asa SL. Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation. Mod Pathol. 2011;24:1545-1552.
30. Elsheikh TM, Asa SL, Chan JK, et al. Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma. Am J Clin Pathol. 2008;130:736-744.
31. Marchevsky AM, Walts AE, Bose S, et al. Evidence-based evaluation of the risks of malignancy predicted by thyroid fine-needle aspiration biopsies. Diagn Cytopathol. 2010;38: 252-259.
32. Walts AE, Bose S, Fan X, et al. A simplified Bethesda system for reporting thyroid cytopathology using only four categories improves intra- and inter-observer diagnostic agreement and provides non-overlapping estimates of malignancy risks. Diagn Cytopathol. 2011 [Epub ahead of print].
33. Shi Y, Ding X, Klein M, et al. Thyroid fine-needle aspiration with atypia of undetermined significance: a necessary or optional category? Cancer. 2009;117:298-304.
34. Bongiovanni M, Crippa S, Baloch Z, et al. Comparison of 5-tiered and 6-tiered diagnostic systems for the reporting of thyroid cytopathology: a multi-institutional study. Cancer Cytopathol. 2011 [Epub ahead of print].
35. Singh RS, Wang HH. Eliminating the 'atypia of undetermined significance/follicular lesion of undetermined significance' category from the bethesda system for reporting thyroid cytopathology. Am J Clin Pathol. 2011;136:896-902.
36. Jing X, Roh MH, Knoepp SM, et al. Minimizing the diagnosis of 'follicular lesion of undetermined significance' and identifying predictive features for neoplasia. Diagn Cytopathol. 2011;39:737-742.
37. Renshaw AA. Subclassification of atypical cells of undetermined significance in direct smears of fine-needle aspirations of the thyroid: distinct patterns and associated risk of malignancy. Cancer Cytopathol. 2011;119:322-327.
38. Abele JS, Levine RA. Diagnostic criteria and risk-adapted approach to indeterminate thyroid cytodiagnosis. Cancer Cytopathol. 2010;118:415-422.
39. VanderLaan PA, Marqusee E, Krane JF. Usefulness of diagnostic qualifiers for thyroid fine-needle aspirations with atypia of undetermined significance. Am J Clin Pathol. 2011; 136:572-577.
40. Lubitz CC, Faquin WC, Yang J, et al. Clinical and cytological features predictive of malignancy in thyroid follicular neoplasms. Thyroid. 2010;20:25-31.
41. Walts AE, Bresee C, Bose S. Can cytomorphology further stratify thyroid fine needle aspirates diagnosed as follicular lesion of undetermined significance? Cytojournal. 2011;8:S66.
42. Jing X, Knoepp SM, Roh MH, et al. Group consensus review minimizes the diagnosis of 'follicular lesion of undetermined significance' and improves cytohistologic concordance. Diagn Cytopathol. 2011 [Epub ahead of print].
43. Nose V. Familial thyroid cancer: a review. Mod Pathol. 2011;24(suppl 2):S19-S33.
44. Marsh DJ, Coulon V, Lunetta KL, et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet. 1998;7: 507-515. (Pubitemid 28120643)
45. Eng C. PTEN: one gene, many syndromes. Hum Mutat. 2003;22:183-198. (Pubitemid 37071635)
46. Harach HR, Soubeyran I, Brown A, et al. Thyroid pathologic findings in patients with Cowden disease. Ann Diagn Pathol. 1999;3:331-340.
47. Stratakis CA, Courcoutsakis NA, Abati A, et al. Thyroid gland abnormalities in patients with the syndrome of spotty skin pigmentation, myxomas, endocrine overactivity, and schwannomas (Carney complex). J Clin Endocrinol Metab. 1997;82:2037-2043. (Pubitemid 27287558)
48. Goto M, Miller RW, Ishikawa Y, et al. Excess of rare cancers in Werner syndrome (adult progeria). Cancer Epidemiol Biomarkers Prev. 1996;5:239-246.
49. Kimura ET, NikiforovaMN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63:1454-1457. (Pubitemid 36373628)
50. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011;7: 569-580.
51. Cohen Y, XingM,Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003;95:625-627. (Pubitemid 36553510)
52. Lima J, Trovisco V, Soares P, et al. BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. J Clin Endocrinol Metab. 2004;89:4267-4271. (Pubitemid 39244424)
53. Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer. 2007;110:38-46.
54. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12:245-262. (Pubitemid 40896444)
55. Kim SW, Lee JI, Kim JW, et al. BRAFV600E mutation analysis in fine-needle aspiration cytology specimens for evaluation of thyroid nodule: a large series in a BRAFV600 E-prevalent population. J Clin Endocrinol Metab. 2010;95: 3693-3700.
56. Kim SK, Hwang TS, Yoo YB, et al. Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status. J Clin Endocrinol Metab. 2011;96:658-664.
57. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88:5399-5404. (Pubitemid 37452745)
58. Begum S, Rosenbaum E, Henrique R, et al. BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Mod Pathol. 2004;17:1359-1363. (Pubitemid 39472990)
59. Kim SY, Yoon J, Ko YS, et al. Constitutive phosphorylation of the FOXO1 transcription factor in gastric cancer cells correlates with microvessel area and the expressions of angiogenesis-related molecules. BMC Cancer. 2011;11:264.
60. Kim TH, Park YJ, Lim JA, et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer. 2011. Epub.
61. Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90:6373-6379. (Pubitemid 41759286)
62. Elisei R, Ugolini C, Viola D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab. 2008;93:3943-3949.
63. Yip L, Nikiforova MN, Carty SE, et al. Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery. 2009;146:1215-1223.
64. Grieco M, Santoro M, Berlingieri MT, et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell. 1990;60:557-563.
65. Santoro M, Dathan NA, Berlingieri MT, et al. Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene. 1994;9:509-516. (Pubitemid 24041530)
66. Santoro M, Carlomagno F, Hay ID, et al. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest. 1992;89:1517-1522.
67. Elisei R, Romei C, Vorontsova T, et al. RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. J Clin Endocrinol Metab. 2001;86:3211-3216. (Pubitemid 32673490)
68. Zhu Z, Ciampi R, Nikiforova MN, et al. Prevalence of RET/ PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J Clin Endocrinol Metab. 2006;91:3603-3610. (Pubitemid 44402144)
69. Ishizaka Y, Kobayashi S, Ushijima T, et al. Detection of retTPC/PTC transcripts in thyroid adenomas and adenomatous goiter by an RT-PCR method. Oncogene. 1991;6:1667-1672. (Pubitemid 21924271)
70. Sheils OM, O'Eary JJ, Uhlmann V, et al. ret/PTC-1 activation in Hashimoto thyroiditis. Int J Surg Pathol. 2000;8:185-189.
71. Suarez HG, du Villard JA, Severino M, et al. Presence of mutations in all three ras genes in human thyroid tumors. Oncogene. 1990;5:565-570.
72. Esapa CT, Johnson SJ, Kendall-Taylor P, et al. Prevalence of Ras mutations in thyroid neoplasia. Clin Endocrinol (Oxf). 1999;50:529-535. (Pubitemid 29193238)
73. Zhu Z, Gandhi M, Nikiforova MN, et al. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol. 2003;120:71-77. (Pubitemid 37046372)
74. Karga H, Lee JK, Vickery AL, et al. Ras oncogene mutations in benign and malignant thyroid neoplasms. J Clin Endocrinol Metab. 1991;73:832-836. (Pubitemid 21921945)
75. Garcia-Rostan G, Zhao H, Camp RL, et al. Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol. 2003;21:3226-3235. (Pubitemid 46606254)
76. Kroll TG, Sarraf P, Pecciarini L, et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science. 2000;289:1357-1360. (Pubitemid 30656054)
77. French CA, Alexander EK, Cibas ES, et al. Genetic and biological subgroups of low-stage follicular thyroid cancer. Am J Pathol. 2003;162:1053-1060. (Pubitemid 36350651)
78. Nikiforova MN, Lynch RA, Biddinger PW, et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab. 2003;88:2318-2326. (Pubitemid 36549913)
79. Marques AR, Espadinha C, Catarino AL, et al. Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab. 2002;87:3947-3952. (Pubitemid 34879553)
80. Nikiforova MN, Biddinger PW, Caudill CM, et al. PAX8- PPAR gamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol. 2002; 26:1016-1023. (Pubitemid 34810562)
81. Castro P, Rebocho AP, Soares RJ, et al. PAX8-PPAR gamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2006;91:213-220. (Pubitemid 43069140)
82. Ito T, Seyama T, Mizuno T, et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res. 1992;52:1369-1371.
83. Garcia-Rostan G, Camp RL, Herrero A, et al. Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol. 2001;158:987-996. (Pubitemid 32221790)
84. Garcia-Rostan G, Costa AM, Pereira-Castro I, et al. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res. 2005;65:10199-10207. (Pubitemid 41743711)
85. Hou P, Liu D, Shan Y, et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res. 2007;13:1161-1170. (Pubitemid 46424056)
86. Dahia PL, Marsh DJ, Zheng Z, et al. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res. 1997;57:4710-4713. (Pubitemid 27468972)
87. Nikiforova MN, Tseng GC, Steward D, et al. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab. 2008;93: 1600-1608. (Pubitemid 351656494)
88. Chen YT, Kitabayashi N, Zhou XK, et al. MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma. Mod Pathol. 2008;21:1139-1146.
89. He H, Jazdzewski K, Li W, et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA. 2005;102:19075-19080. (Pubitemid 43049568)
90. Nikiforova MN, Chiosea SI, Nikiforov YE. MicroRNA expression profiles in thyroid tumors. Endocr Pathol. 2009; 20:85-91.
91. Weber F, Teresi RE, Broelsch CE, et al. A limited set of human microRNA is deregulated in follicular thyroid carcinoma. J Clin Endocrinol Metab. 2006;91:3584-3591. (Pubitemid 44402141)
92. Visone R, Pallante P, Vecchione A, et al. Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene. 2007;26:7590-7595. (Pubitemid 350207711)
93. Ohori NP, Nikiforova MN, Schoedel KE, et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of 'follicular lesion of undetermined significance/atypia of undetermined significance'. Cancer Cytopathol. 2010;118: 17-23.
94. Cantara S, Capezzone M, Marchisotta S, et al. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab. 2010;95:1365-1369.
95. Nikiforov YE, Steward DL, Robinson-Smith TM, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 2009;94:2092-2098.
96. Nikiforov YE. Molecular analysis of thyroid tumors. Mod Pathol. 2011;24(suppl 2):S34-S43.
97. Salvatore G, Giannini R, Faviana P, et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fineneedle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2004;89:5175-5180. (Pubitemid 39391466)
98. Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 2011;96:3390-3397.
99. O'Neill CJ, Bullock M, Chou A, et al. BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery. 2010;148:1139-1145. Discussion 1145-1146.
100. Ricarte-Filho JC, Ryder M, Chitale DA, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 2009; 69:4885-4893.
101. Durante C, Puxeddu E, Ferretti E, et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab. 2007;92: 2840-2843. (Pubitemid 47037399)
102. Xing M. Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol. 2010;321:86-93.
103. Sherman SI. Targeted therapy of thyroid cancer. Biochem Pharmacol. 2010;80:592-601.
104. Lin KL, Wang OC, Zhang XH, et al. The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol. 2010;17: 3294-3300.
105. Kwak JY, Kim EK, Chung WY, et al. Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. Radiology. 2009;253:854-860.
106. Lee X, Gao M, Ji Y, et al. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol. 2009;16:240-245.
107. Rodolico V, Cabibi D, Pizzolanti G, et al. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid
108. Howell GM, Carty SE, Armstrong MJ, et al. Both BRAF V600E mutation and older age (>/=65 years) are associated with recurrent papillary thyroid cancer. Ann Surg Oncol. 2011;18:3566-3571.
109. Niemeier LA, Kuffner Akatsu H, Song C, et al. A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer. 2011 [Epub ahead of print].